Cover Image
市場調查報告書

急性呼吸窘迫症(ARDS):開發平台分析

Acute Respiratory Distress Syndrome - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 192441
出版日期 內容資訊 英文 96 Pages
訂單完成後即時交付
價格
Back to Top
急性呼吸窘迫症(ARDS):開發平台分析 Acute Respiratory Distress Syndrome - Pipeline Review, H2 2017
出版日期: 2017年07月18日 內容資訊: 英文 96 Pages
簡介

急性呼吸窘迫症(ARDS)是肺中具有彈性的小氣囊(肺泡)積留體液造成的。常見的根本原因有敗血症,吸入有害物質,嚴重肺炎,頭部和胸部的外傷等。徵兆與症狀有嚴重的呼吸急促,呼吸困難,異常快的呼吸,低血壓,精神混亂,極度的疲勞等。

本報告提供急性呼吸窘迫症(ARDS)的治療藥之開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

急性呼吸窘迫症(ARDS)概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

正在開發的治療藥:各企業

調查中的治療藥:大學/研究機別關

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

開發中的產品:各企業

調查中的產品:大學/研究機別

開發治療藥的企業

  • Altor BioScience Corporation
  • Athersys, Inc.
  • Faron Pharmaceuticals Oy
  • FirstString Research, Inc.
  • GlaxoSmithKline Plc
  • Histocell S.L.
  • Phylogica Limited
  • Serendex Pharmaceuticals A/S
  • Silence Therapeutics Plc
  • Therabron Therapeutics, Inc.

治療藥的評估

  • 單獨療法的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • ALT-836
  • BIO-10901
  • CG-367
  • Cyndacel-M
  • GSK-2586881
  • GSK-2862277
  • interferon beta-1a
  • molgramostim
  • Monoclonal Antibodies to Inhibit uPA for Infectious Disease and Respiratory Disorders
  • Oligonucleotide to Inhibit Endothelin-1 for Pulmonary Arterial Hypertension
  • PF-05285401
  • PYC-35
  • PYC-36
  • PYC-38
  • PYC-98
  • Recombinant Proteins for Acute Lung Injury and Acute Respiratory Distress Syndrome
  • S-1229
  • SAN-101
  • Small Molecule to Inhibit MMP and Cytokine for Immunology, Respiratory and Musculoskeletal Disorders
  • Stem Cell Therapy for Inflammatory Lung Diseases
  • Stromal Cell Therapy for Acute Respiratory Distress Syndrome
  • Synthetic Peptide for Acute Lung Injury and Acute Respiratory Distress Syndrome

開發中產品的最新趨勢

暫停的計劃

開發中止的產品

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9571IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Respiratory Distress Syndrome - Pipeline Review, H2 2017, provides an overview of the Acute Respiratory Distress Syndrome (Respiratory) pipeline landscape.

Acute respiratory distress syndrome (ARDS) occurs when fluid fills up the air sacs in lungs. This leads to low oxygen levels in the blood. Common causes of ARDS include sepsis, inhalation of harmful substances, severe pneumonia and head or chest injury. Signs and symptoms of ARDS include severe shortness of breath, labored and unusually rapid breathing, low blood pressure and confusion and extreme tiredness.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acute Respiratory Distress Syndrome - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Acute Respiratory Distress Syndrome (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acute Respiratory Distress Syndrome (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Acute Respiratory Distress Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 5, 2, 1, 9 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Acute Respiratory Distress Syndrome (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Respiratory Distress Syndrome (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Acute Respiratory Distress Syndrome (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Acute Respiratory Distress Syndrome (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Acute Respiratory Distress Syndrome (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Acute Respiratory Distress Syndrome (Respiratory)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Acute Respiratory Distress Syndrome (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Acute Respiratory Distress Syndrome (Respiratory) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Acute Respiratory Distress Syndrome - Overview
  • Acute Respiratory Distress Syndrome - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Acute Respiratory Distress Syndrome - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Acute Respiratory Distress Syndrome - Companies Involved in Therapeutics Development
  • Athersys Inc
  • Commence Bio Inc
  • Cynata Therapeutics Ltd
  • Faron Pharmaceuticals Oy
  • GlaxoSmithKline Plc
  • Hydra Biosciences Inc
  • Implicit Bioscience Ltd
  • Navigen Inc
  • ProMetic Life Sciences Inc
  • Savara Inc
  • Silence Therapeutics Plc
  • SolAeroMed Inc
  • Windtree Therapeutics Inc
  • Acute Respiratory Distress Syndrome - Drug Profiles
  • Aerosurf - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BIO-10901 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CMB-200 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • GSK-2586881 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • GSK-2862277 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • HC-067047 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • IC-14 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • interferon beta-1a - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • LT-1001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • lucinactant - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • molgramostim - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Monoclonal Antibodies to Inhibit uPA for Acute Lung Injury,Acute Respiratory Distress Syndrome and Sepsis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NAV-5093 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Oligonucleotide to Inhibit Endothelin-1 for Lung Cancer, Pulmonary Arterial Hypertension and Respiratory Disorders - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PF-05285401 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • plasminogen (human) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • S-1229 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SAN-101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • simvastatin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Stem Cell Therapy for Acute Respiratory Distress Syndrome - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Stem Cell Therapy for Acute Respiratory Distress Syndrome - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TCP-25 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Acute Respiratory Distress Syndrome - Dormant Projects
  • Acute Respiratory Distress Syndrome - Discontinued Products
  • Acute Respiratory Distress Syndrome - Product Development Milestones
  • Featured News & Press Releases
  • May 08, 2017: Faron Pharmaceuticals: Update on INTEREST Phase III Study for Traumakine in ARDS from IDMC
  • Oct 31, 2016: New Patent Application Accepted by Finnish Patent Office Protect the intravenous use of interferon-beta in a novel formulation
  • Oct 24, 2016: First Traumakine Phase III patient in Japan recruited for the treatment of acute respiratory distress syndrome and Update on Pan-European Phase III Traumakine trial
  • Sep 03, 2016: Queen's University Developing New Drug against Leading Causes of Death in the UK - Sepsis and Ards
  • May 25, 2016: First patient dosed in Savaras pivotal trial for PAP
  • Mar 01, 2016: Faron files patent application to further strengthen protection for its novel Traumakine (FP-1201-lyo) formulation
  • Jan 07, 2016: Positive top-line results from the Japanese Phase II study of Traumakine for the treatment of ARDS
  • Dec 29, 2015: First Patient recruited in Pan-European Phase III INTEREST study for treatment of acute respiratory distress syndrome
  • Oct 19, 2015: Serendex to initiate pivotal phase II/III clinical trial for PAP
  • Aug 09, 2015: Serendex to initiate first phase II clinical trial
  • Jun 10, 2015: Recruitment of ARDS patients for Serendex phase II clinical trial to commence in November
  • May 27, 2015: Phase I clinical trial of inhaled molgramostim has commenced
  • May 20, 2015: Novozymes Biopharma enables stable formulation of Serendex Pharmaceutical's inhalable biological drug for treatment of severe pulmonary diseases
  • May 10, 2015: Positive topline data from Serendex phase I clinical trial
  • Feb 27, 2015: Serendex submits phase I application
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Acute Respiratory Distress Syndrome, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Acute Respiratory Distress Syndrome - Pipeline by Athersys Inc, H2 2017
  • Acute Respiratory Distress Syndrome - Pipeline by Commence Bio Inc, H2 2017
  • Acute Respiratory Distress Syndrome - Pipeline by Cynata Therapeutics Ltd, H2 2017
  • Acute Respiratory Distress Syndrome - Pipeline by Faron Pharmaceuticals Oy, H2 2017
  • Acute Respiratory Distress Syndrome - Pipeline by GlaxoSmithKline Plc, H2 2017
  • Acute Respiratory Distress Syndrome - Pipeline by Hydra Biosciences Inc, H2 2017
  • Acute Respiratory Distress Syndrome - Pipeline by Implicit Bioscience Ltd, H2 2017
  • Acute Respiratory Distress Syndrome - Pipeline by Navigen Inc, H2 2017
  • Acute Respiratory Distress Syndrome - Pipeline by ProMetic Life Sciences Inc, H2 2017
  • Acute Respiratory Distress Syndrome - Pipeline by Savara Inc, H2 2017
  • Acute Respiratory Distress Syndrome - Pipeline by Silence Therapeutics Plc, H2 2017
  • Acute Respiratory Distress Syndrome - Pipeline by SolAeroMed Inc, H2 2017
  • Acute Respiratory Distress Syndrome - Pipeline by Windtree Therapeutics Inc, H2 2017
  • Acute Respiratory Distress Syndrome - Dormant Projects, H2 2017
  • Acute Respiratory Distress Syndrome - Dormant Projects, H2 2017 (Contd..1), H2 2017
  • Acute Respiratory Distress Syndrome - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Acute Respiratory Distress Syndrome, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Top 10 Molecule Types, H2 2017
  • Number of Products by Stage and Top 10 Molecule Types, H2 2017
Back to Top